This is a Denmark news story, published by Wired, that relates primarily to Mullin news.
For more Denmark news, you can click here:
more Denmark newsFor more Mullin news, you can click here:
more Mullin newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Wired, you can click here:
more news from WiredOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
diabetes drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest American Diabetes Association news, insulin news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
obesity drugsWired
•73% Informative
The next wave of obesity drugs could help people lose even more weight—and make some pharma companies a fortune.
Researchers are racing to develop new anti-obesity medications that are more effective, more convenient, or produce fewer side effects.
Having more drugs on the market would mean more choices for patients.
Amgen is working on an injectable drug called MariTide that would be given just once a month.
Other companies are pursuing drugs with different targets that could be used on their own or in combination with GLP-1 drugs.
Denmark -based firm Zealand Pharma is developing a drug called petrelintide that mimics a hormone called amylin .
“With this flurry of activity, we’re probably going to see some very exciting new medicines that could be even better than the ones we have now," says Mullin .
Mullin is a staff writer at WIRED, covering biotechnology.
She served as an associate editor at MIT Technology Review , where she wrote about biomedicine.
VR Score
63
Informative language
57
Neutral language
11
Article tone
semi-formal
Language
English
Language complexity
46
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
14
Source diversity
11
Affiliate links
no affiliate links